Tongling-based biologic/personal-care technology company; specific product lines not independently confirmed.
Tongling-based biologic/personal-care technology company; specific product lines not independently confirmed.
Moat: none
Headquarters: Tongling, China · Employees: 647
Size Tongling Jieya Biologic Technology (301108.SZ) is a China Consumer Staples company (Household/Personal Care) with a market value of $933M, the 2291st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥39.50 on 18 Nov 2026.
Performance Over six months the shares gained 56.2%, against +4.3% for the median peer and -20.0% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 24.3% over the last twelve months (peer median +10.2%); the operating margin is 5.0% (peer median 8.9%).
Valuation It trades at 52.5× forward earnings against a peer median of 18.7× (most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.7 points below its cost of capital (6.2% WACC).
Next results Next results expected around 15 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥875M | CN¥771M | CN¥546M | CN¥618M | CN¥664M |
| Revenue growth | — | +41% | -12% | -7% | — |
| Gross profit | CN¥234M | CN¥178M | CN¥94.9M | CN¥173M | CN¥203M |
| EBITDA | n/a | CN¥130M | CN¥62.7M | CN¥136M | CN¥169M |
| Net income | CN¥54.5M | CN¥77.3M | CN¥19.5M | CN¥115M | CN¥141M |
| Free cash flow | CN¥30.1M | -CN¥219M | CN¥20.7M | CN¥11.3M | CN¥282M |
| Capital expenditure | CN¥219M | CN¥368M | CN¥96.2M | CN¥85.1M | CN¥29.9M |
| Total debt | CN¥336M | CN¥172M | CN¥80.1M | CN¥105M | CN¥121M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301108.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.1% | -1.6% | 3rd lowest of 21 |
| 6-month return | +56.2% | +4.3% | 2nd highest of 21 |
| Distance from 52-week high | -30.2% | -33.1% | 10th highest of 21 |
| Revenue growth (TTM) | +24.3% | +10.2% | 7th highest of 21 |
| Operating margin | 5.0% | 8.9% | 5th lowest of 21 |
| Forward P/E | 52.5× | 18.7× | most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 28.5% | 4.4% | 3rd most demanding of 18 |
| Growth delivered (Del g) | +0.8% | +8.9% | 3rd lowest of 18 |
| Hurdle (Req g minus delivered) | +27.7 pp | -4.4 pp | most demanding of 18 |
| ROIC minus cost of capital | -0.7 pp | +7.1 pp | 6th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tongling Jieya Biologic Technology 301108.SZ | China | $933M | +56% | +24% | 5% | 52.5× | 28.5% | +0.8% |
| Runben Biotechnology 603193.SS | China | $918M | -30% | +13% | 21% | 18.5× | 1.5% | +28.4% |
| Dencare (Chongqing) Oral Care 001328.SZ | China | $912M | +13% | +10% | 11% | 27.9× | 3.7% | +10.8% |
| Noevir 4928.T | Japan | $978M | +7% | -3% | 28% | 20.4× | -12.8% | +4.1% |
| Cosmecca Korea 241710.KS | South Korea | $847M | +23% | +42% | 12% | 16.3× | n/a | n/a |
| Galaxy Surfactants GALAXYSURF.NS | India | $845M | +22% | +30% | 9% | 17.6× | 18.5% | +13.7% |
| Shanghai Forest Cabin Cosmetics 2657.HK | Hong Kong | $1.04B | +15% | +74% | 18% | 11.8× | 11.3% | +49.0% |
| SYoung 300740.SZ | China | $816M | -48% | +14% | 3% | 33.4× | 14.0% | +6.1% |
| d'Alba Global 483650.KS | South Korea | $1.13B | -55% | +49% | 22% | 12.0× | -6.6% | +53.0% |
| Jyothy Labs JYOTHYLAB.NS | India | $762M | -9% | +5% | 8% | 40.8× | 34.5% | +8.9% |
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.17B | -42% | +23% | 8% | 14.4× | -6.1% | +21.2% |
| Milbon 4919.T | Japan | $743M | +48% | +8% | 14% | 25.7× | -3.3% | +8.2% |
| Hangzhou Haoyue Personal Care 605009.SS | China | $726M | -18% | +10% | 6% | 17.7× | 4.4% | +7.7% |
| Edgewell Personal Care EPC | United States | $1.30B | +67% | -10% | 7% | 14.2× | n/a | n/a |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.35B | +27% | 0% | 3% | 37.3× | 28.8% | +22.8% |
| Intercos ICOS.MI | Italy | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% | +11.5% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| Bajaj Consumer Care BAJAJCON.NS | India | $560M | -24% | +29% | 22% | 19.7× | 14.8% | +5.0% |
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |